RT Journal Article
SR Electronic
T1 Symptomatic SARS-CoV-2 re-infection of a health care worker in a Belgian nosocomial outbreak despite primary neutralizing antibody response
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.05.20225052
DO 10.1101/2020.11.05.20225052
A1 Selhorst, Philippe
A1 Van Ierssel, Sabrina
A1 Michiels, Jo
A1 Mariën, Joachim
A1 Bartholomeeusen, Koen
A1 Dirinck, Eveline
A1 Vandamme, Sarah
A1 Jansens, Hilde
A1 Ariën, Kevin K.
YR 2020
UL http://medrxiv.org/content/early/2020/11/09/2020.11.05.20225052.abstract
AB Background It is currently unclear whether SARS-CoV-2 re-infection will remain a rare event, only occurring in individuals who fail to mount an effective immune response, or whether it will occur more frequently when humoral immunity wanes following primary infection.Methods A case of re-infection was observed in a Belgian nosocomial outbreak involving 3 patients and 2 health care workers. To distinguish re-infection from persistent infection and detect potential transmission clusters, whole genome sequencing was performed on nasopharyngeal swabs of all individuals including the re-infection case’s first episode. IgA, IgM, and IgG and neutralizing antibody responses were quantified in serum of all individuals, and viral infectiousness was measured in the swabs of the reinfection case.Results Re-infection was confirmed in a young, immunocompetent health care worker as viral genomes derived from the first and second episode belonged to different SARS-CoV-2 clades. The symptomatic re-infection occurred after an interval of 185 days, despite the development of an effective humoral immune response following symptomatic primary infection. The second episode, however, was milder and characterized by a fast rise in serum IgG and neutralizing antibodies. Although contact tracing and virus culture remained inconclusive, the health care worker formed a transmission cluster with 3 patients and showed evidence of virus replication but not of neutralizing antibodies in her nasopharyngeal swabs.Conclusion If this case is representative of most Covid-19 patients, long-lived protective immunity against SARS-CoV-2 might not be likely.Competing Interest StatementThe authors have declared no competing interest.Funding StatementPS and JM are members of the Institute of Tropical Medicine's Outbreak Research Team which is financially supported by the Department of Economy, Science and Innovation (EWI) of the Flemish government. Part of the research was covered by the Flemish Research Foundation [grant number FWO-G0G4220N to KA]. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Antwerp university hospital EC/PM/nvb/2020.084All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll raw data are available through corresponding author or presented in the manuscript